Scoop: Martin Shkreli bats back a coup at Turing, new board considers a sale of assets
Martin Shkreli had a little business to attend to before his fraud trial got started in Brooklyn today.
In a showdown last week with chief scientist and CEO Eliseo Salinas, Shkreli handily orchestrated a sweep of the board at Turing Pharmaceuticals, gaining the election of 5 new board members — a group that includes several executives with close business ties to Shkreli. And Turing says in a statement that it will follow up on ongoing negotiations aimed at selling the biotech’s stock and assets, which are topped by Daraprim.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.